Compare Merck & Co., Inc. (MRK) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Clear Secure Inc — how do they compare? Merck & Co., Inc. trades at $145 (market cap $351.28B), while Clear Secure Inc trades at $43.26 (market cap $4.44B). The key difference: Merck & Co., Inc. is far larger — about 79.1× Clear Secure Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Clear Secure Inc for 19 Days on average.
| MRK | YOU | |
|---|---|---|
Market Cap | $351.28B | $4.44B |
Volume | 7,969,665 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $156.43 | $62.36 |
52-Week Low | $82.49 | $29.61 |
Typical Hold Time | 98 Days | 19 Days |
Enterprise Value | $398.04B | $3.59B |
Dividend Yield | 2.39% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Clear Secure (YOU) trades at $43.26, up 1.59% today, with a bullish technical signal despite mixed moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Profitability remains robust with a net margin of 14.78% and ROE of 90.29%, though valuation multiples like P/E of 29.11 appear elevated. Recent news highlights strategic partnerships, such as the integration with CrowdStrike's Falcon platform, and the launch of corporate memberships.
The outlook is positive given earnings momentum and expanding market opportunities, but risks include high valuation sensitivity and competitive pressures. Analysts are generally bullish with a consensus price target of $61.40, implying significant upside, though insider selling and overbought RSI levels warrant caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
